These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 2404820)

  • 1. Activation of prodrugs by antibody-enzyme conjugates: a new approach to cancer therapy.
    Senter PD
    FASEB J; 1990 Feb; 4(2):188-93. PubMed ID: 2404820
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selective activation of anticancer prodrugs by monoclonal antibody-enzyme conjugates.
    Wallace PM; Senter PD
    Methods Find Exp Clin Pharmacol; 1994 Sep; 16(7):505-12. PubMed ID: 7885077
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor targeting: activation of prodrugs by enzyme-monoclonal antibody conjugates.
    Huennekens FM
    Trends Biotechnol; 1994 Jun; 12(6):234-9. PubMed ID: 7765070
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Generation of cytotoxic agents by targeted enzymes.
    Senter PD; Wallace PM; Svensson HP; Vrudhula VM; Kerr DE; Hellström I; Hellström KE
    Bioconjug Chem; 1993; 4(1):3-9. PubMed ID: 8431510
    [No Abstract]   [Full Text] [Related]  

  • 5. Selective activation of anticancer prodrugs by monoclonal antibody-enzyme conjugates.
    Senter PD; Springer CJ
    Adv Drug Deliv Rev; 2001 Dec; 53(3):247-64. PubMed ID: 11744170
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Folate-targeted enzyme prodrug cancer therapy utilizing penicillin-V amidase and a doxorubicin prodrug.
    Lu JY; Lowe DA; Kennedy MD; Low PS
    J Drug Target; 1999; 7(1):43-53. PubMed ID: 10614814
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Developments with targeted enzymes in cancer therapy.
    Bagshawe KD; Sharma SK; Burke PJ; Melton RG; Knox RJ
    Curr Opin Immunol; 1999 Oct; 11(5):579-83. PubMed ID: 10508703
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-tumor effects of antibody-alkaline phosphatase conjugates in combination with etoposide phosphate.
    Senter PD; Saulnier MG; Schreiber GJ; Hirschberg DL; Brown JP; Hellström I; Hellström KE
    Proc Natl Acad Sci U S A; 1988 Jul; 85(13):4842-6. PubMed ID: 3387440
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting enzymes for cancer therapy: old enzymes in new roles.
    Deonarain MP; Epenetos AA
    Br J Cancer; 1994 Nov; 70(5):786-94. PubMed ID: 7947082
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The choice of prodrugs for gene directed enzyme prodrug therapy of cancer.
    Connors TA
    Gene Ther; 1995 Dec; 2(10):702-9. PubMed ID: 8750009
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antibody-enzyme conjugates for cancer therapy.
    Melton RG; Sherwood RF
    J Natl Cancer Inst; 1996 Feb; 88(3-4):153-65. PubMed ID: 8632489
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antibody-directed enzyme/prodrug therapy (ADEPT).
    Bagshawe KD
    Biochem Soc Trans; 1990 Oct; 18(5):750-2. PubMed ID: 2083666
    [No Abstract]   [Full Text] [Related]  

  • 13. Site-specific prodrug activation by antibody-beta-lactamase conjugates: preclinical investigation of the efficacy and toxicity of doxorubicin delivered by antibody directed catalysis.
    Meyer DL; Law KL; Payne JK; Mikolajczyk SD; Zarrinmayeh H; Jungheim LN; Kling JK; Shepherd TA; Starling JJ
    Bioconjug Chem; 1995; 6(4):440-6. PubMed ID: 7578364
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antibody directed enzyme prodrug therapy (ADEPT): a review of the experimental and clinical considerations.
    Syrigos KN; Epenetos AA
    Anticancer Res; 1999; 19(1A):605-13. PubMed ID: 10226606
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prodrugs in cancer chemotherapy.
    Connors TA; Knox RJ
    Stem Cells; 1995 Sep; 13(5):501-11. PubMed ID: 8528099
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intratumoral generation of 5-fluorouracil mediated by an antibody-cytosine deaminase conjugate in combination with 5-fluorocytosine.
    Wallace PM; MacMaster JF; Smith VF; Kerr DE; Senter PD; Cosand WL
    Cancer Res; 1994 May; 54(10):2719-23. PubMed ID: 8168103
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potentiation of antitumor immunity by antibody-directed enzyme prodrug therapy.
    Chen BM; Cheng TL; Tzou SC; Roffler SR
    Int J Cancer; 2001 Dec; 94(6):850-8. PubMed ID: 11745488
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recent developments in gene-directed enzyme prodrug therapy (GDEPT) for cancer.
    Niculescu-Duvaz I; Cooper RG; Stribbling SM; Heyes JA; Metcalfe JA; Springer CJ
    Curr Opin Mol Ther; 1999 Aug; 1(4):480-6. PubMed ID: 11713763
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetic delivery of enzymes for cancer therapy.
    Deonarain MP; Spooner RA; Epenetos AA
    Gene Ther; 1995 Jun; 2(4):235-44. PubMed ID: 7552983
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Receptor-mediated and enzyme-dependent targeting of cytotoxic anticancer drugs.
    Dubowchik GM; Walker MA
    Pharmacol Ther; 1999 Aug; 83(2):67-123. PubMed ID: 10511457
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.